Cargando…

Circulating levels of MOTS-c in patients with breast cancer treated with metformin

The mitokine MOTS-c is a mitochondrially-encoded “exercise-mimetic peptide” expressed in multiple tissues, particularly skeletal muscles, which can be detected as a circulating hormone in the blood. MOTS-c mechanisms of action (MoA) involve insulin sensitization, enhanced glucose utilization, suppre...

Descripción completa

Detalles Bibliográficos
Autores principales: Cuyàs, Elisabet, Verdura, Sara, Martin-Castillo, Begoña, Menendez, Javier A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10008497/
https://www.ncbi.nlm.nih.gov/pubmed/36490309
http://dx.doi.org/10.18632/aging.204423
_version_ 1784905771710939136
author Cuyàs, Elisabet
Verdura, Sara
Martin-Castillo, Begoña
Menendez, Javier A.
author_facet Cuyàs, Elisabet
Verdura, Sara
Martin-Castillo, Begoña
Menendez, Javier A.
author_sort Cuyàs, Elisabet
collection PubMed
description The mitokine MOTS-c is a mitochondrially-encoded “exercise-mimetic peptide” expressed in multiple tissues, particularly skeletal muscles, which can be detected as a circulating hormone in the blood. MOTS-c mechanisms of action (MoA) involve insulin sensitization, enhanced glucose utilization, suppression of mitochondrial respiration, and targeting of the folate-AICAR-AMPK pathway. Although MOTS-c MoA largely overlap those of the anti-diabetic biguanide metformin, the putative regulatory actions of metformin on MOTS-c have not yet been evaluated in detail. Here, we measured circulating MOTS-c in paired baseline and post-treatment sera obtained from HER2-positive breast cancer patients randomized to receive either metformin combined with neoadjuvant chemotherapy and trastuzumab or an equivalent regimen without metformin. We failed to find any significant alteration of circulating MOTS-c –as measured using the commercially available competitive ELISA CEX132Hu– in response to 24 weeks of a neoadjuvant chemotherapy/trastuzumab regimen with or without daily metformin. Changes in circulating MOTS-c levels failed to reach statistical significance when comparing patients achieving pathological complete response (pCR), irrespective of metformin treatment. The inability of metformin to target skeletal muscle, the major tissue for MOTS-c production and secretion, might limit its regulatory effects on circulating MOTS-c. Further studies are needed to definitely elucidate the nature of the interaction between metformin and MOTS-c in cancer and non-cancer patients.
format Online
Article
Text
id pubmed-10008497
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Impact Journals
record_format MEDLINE/PubMed
spelling pubmed-100084972023-03-13 Circulating levels of MOTS-c in patients with breast cancer treated with metformin Cuyàs, Elisabet Verdura, Sara Martin-Castillo, Begoña Menendez, Javier A. Aging (Albany NY) Research Perspective The mitokine MOTS-c is a mitochondrially-encoded “exercise-mimetic peptide” expressed in multiple tissues, particularly skeletal muscles, which can be detected as a circulating hormone in the blood. MOTS-c mechanisms of action (MoA) involve insulin sensitization, enhanced glucose utilization, suppression of mitochondrial respiration, and targeting of the folate-AICAR-AMPK pathway. Although MOTS-c MoA largely overlap those of the anti-diabetic biguanide metformin, the putative regulatory actions of metformin on MOTS-c have not yet been evaluated in detail. Here, we measured circulating MOTS-c in paired baseline and post-treatment sera obtained from HER2-positive breast cancer patients randomized to receive either metformin combined with neoadjuvant chemotherapy and trastuzumab or an equivalent regimen without metformin. We failed to find any significant alteration of circulating MOTS-c –as measured using the commercially available competitive ELISA CEX132Hu– in response to 24 weeks of a neoadjuvant chemotherapy/trastuzumab regimen with or without daily metformin. Changes in circulating MOTS-c levels failed to reach statistical significance when comparing patients achieving pathological complete response (pCR), irrespective of metformin treatment. The inability of metformin to target skeletal muscle, the major tissue for MOTS-c production and secretion, might limit its regulatory effects on circulating MOTS-c. Further studies are needed to definitely elucidate the nature of the interaction between metformin and MOTS-c in cancer and non-cancer patients. Impact Journals 2022-12-06 /pmc/articles/PMC10008497/ /pubmed/36490309 http://dx.doi.org/10.18632/aging.204423 Text en Copyright: © 2023 Cuyàs et al. https://creativecommons.org/licenses/by/3.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/3.0/) (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Perspective
Cuyàs, Elisabet
Verdura, Sara
Martin-Castillo, Begoña
Menendez, Javier A.
Circulating levels of MOTS-c in patients with breast cancer treated with metformin
title Circulating levels of MOTS-c in patients with breast cancer treated with metformin
title_full Circulating levels of MOTS-c in patients with breast cancer treated with metformin
title_fullStr Circulating levels of MOTS-c in patients with breast cancer treated with metformin
title_full_unstemmed Circulating levels of MOTS-c in patients with breast cancer treated with metformin
title_short Circulating levels of MOTS-c in patients with breast cancer treated with metformin
title_sort circulating levels of mots-c in patients with breast cancer treated with metformin
topic Research Perspective
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10008497/
https://www.ncbi.nlm.nih.gov/pubmed/36490309
http://dx.doi.org/10.18632/aging.204423
work_keys_str_mv AT cuyaselisabet circulatinglevelsofmotscinpatientswithbreastcancertreatedwithmetformin
AT verdurasara circulatinglevelsofmotscinpatientswithbreastcancertreatedwithmetformin
AT martincastillobegona circulatinglevelsofmotscinpatientswithbreastcancertreatedwithmetformin
AT menendezjaviera circulatinglevelsofmotscinpatientswithbreastcancertreatedwithmetformin
AT circulatinglevelsofmotscinpatientswithbreastcancertreatedwithmetformin